Parkinson’s Disease – Global Clinical Trials Review, 2026

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

GlobalData's clinical trial report, “Parkinson's Disease – Global Clinical Trials Review, 2026" provides an overview of Parkinson's Disease Clinical trials scenario. This report provides top line data relating to the clinical trials on Parkinson's Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma – Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

AbbVie Inc
UCB SA
Teva Pharmaceutical Industries Ltd
Bial Holding SA
C. H. Boehringer Sohn AG & Co KG
The Lundbeck Foundation
Newron Pharmaceuticals SpA
Novartis AG
Kirin Holdings Co Ltd
Pfizer Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Report Guidance

GlobalData Clinical Trials Report Coverage

Clinical Trials by Region

Clinical Trials and Average Enrollment by Country

Top Five Countries Contributing to Clinical Trials in Asia-Pacific

Top Five Countries Contributing to Clinical Trials in Europe

Top Countries Contributing to Clinical Trials in North America

Top Five Countries Contributing to Clinical Trials in Middle East and Africa

Top Five Countries Contributing to Clinical Trials in Central and South America

Clinical Trials by G7 Countries: Proportion of Parkinson's Disease to Central Nervous System Clinical Trials

Clinical Trials by Phase in G7 Countries

Clinical Trials in G7 Countries by Trial Status

Clinical Trials by E7 Countries: Proportion of Parkinson's Disease to Central Nervous System Clinical Trials

Clinical Trials by Phase in E7 Countries

Clinical Trials in E7 Countries by Trial Status

Clinical Trials by Phase

In Progress Trials by Phase

Clinical Trials by Trial Status

Clinical Trials by End Point Status

Subjects Recruited Over a Period of Time

Clinical Trials by Sponsor Type

Prominent Sponsors

Top Companies Participating in Parkinson's Disease Therapeutics Clinical Trials

Prominent Drugs

Latest Clinical Trials News on Parkinson's Disease

Jan 27, 2026: Bial Achieves Key Milestone in Phase 2B ACTIVATE Study of BIA 28-6156 in GBA1-Associated Parkinson’s Disease

Jan 23, 2026: Insilico Medicine Receives IND Approval From FDA for ISM8969, an AI-Empowered Potential Best-In-Class NLRP3 Inhibitor

Jan 20, 2026: Olatec Therapeutics Presented Preclinical Evidence of Disease-Modifying Activity with Dapansutrile in its Parkinson's Studies

Jan 15, 2026: Brenig Therapeutics Provides Update on BT-267, its LRRK2 Program

Jan 15, 2026: Brenig Therapeutics Announces Initiation of First-in-Human Study of BT-409, a Brain-Selective NLRP3 Inhibitor

Jan 09, 2026: NRG doses first participants in Phase I trial for ALS and Parkinson’s

Jan 08, 2026: BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson’s Disease

Jan 07, 2026: Herantis Pharma – Phase 1B Biomarker Data Show Clear Evidence of Biological Response to Her-096 in People With Parkinson’s Disease

Jan 07, 2026: Bial Launches KYNMOBI (Apomorphine Hydrochloride) in the United Kingdom

Jan 06, 2026: Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287

Jan 05, 2026: Kenai Receives $8M Grant from California Institute for Regenerative Medicine (CIRM) to Advance RNDP-001 for Idiopathic Parkinson's Disease

Dec 23, 2025: Parkinson’s stem cell therapy demonstrates promise in Phase II trial

Dec 23, 2025: IRLAB Receives Approval for a Phase Ib Study with IRL757 in Parkinson's Disease

Dec 22, 2025: Zambon Biotech Announces First Patient Dosed in Phase 3B ADIP Clinical Study of IPX203 in Parkinson’s Disease

Dec 18, 2025: Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint From Its Phase 1B Clinical Study of GT-02287 in People With PD

Dec 18, 2025: Gain Therapeutics to Virtual KOL Event on GT-02287 for Parkinson’s Disease

Dec 15, 2025: Kenai Announces First Patient Dosed in Phase 1 REPLACE Clinical Trial of Neuron Replacement Cell Therapy RNDP-001 for Idiopathic Parkinson's Disease

Dec 11, 2025: AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease

Dec 10, 2025: Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program

Dec 09, 2025: AskBio’s AB-1005 Receive Pioneering Regenerative Medical Product Designation in Japan

Dec 05, 2025: Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT for Parkinson’s Disease

Dec 05, 2025: Cerevance Showcases Positive Phase 2 Results Demonstrating Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinson’s Disease

Nov 26, 2025: Herantis Pharma Announces Successful Completion of Six-Month GLP Toxicology Study of HER-096

Nov 24, 2025: Cerevance to Highlight Potential of Solengepras in Parkinson’s Disease at the 2025 Parkinson Study Group Annual Meeting

Nov 24, 2025: Annovis Announces Two Presentations at the CTAD 2025 Conference

Nov 24, 2025: Approval Obtained for the Group’s New Drug LY03017 for Clinical Trials in the U.S.

Nov 20, 2025: Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025

Nov 17, 2025: Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

Nov 17, 2025: Karolinska Portfolio Company Umecrine Cognition Publishes Data on the Benefits of Early Treatment With Golexanolone in Parkinson’s Disease

Nov 15, 2025: BrainXell Showcases Pioneering iPSC Research and Promising In Vivo Data for BXT-110 for Parkinson's Disease at 2025 Society for Neuroscience Meeting

Nov 13, 2025: Booster Therapeutics Awarded Grant From the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to Advance New Class of Phase 1 Study

Nov 13, 2025: Aldeyra Therapeutics Announces Expansion of RASP Platform To Include Central Nervous System Diseases and Provides Updates on Reproxalap

Nov 11, 2025: CND Life Sciences’ Syn-One Biomarker Services Used for Novel Parkinson’s Disease Endpoint in Phase 2 Drug Trial

Nov 07, 2025: IRLAB Receives Acceptance for Two Abstracts at AD/PD(TM) 2026: The 20th International Conference on Alzheimer's and Parkinson's Diseases

Nov 05, 2025: Jupiter Neurosciences Receives FDA Clearance of IND Application To Initiate Phase 2A Clinical Trial of JOTROL in Parkinson’s Disease

Nov 03, 2025: Serina Therapeutics Provides Regulatory Update on SER-252 Program

Nov 03, 2025: BrainXell Unveils Promising Preclinical Data Demonstrating Efficacy of BXT-110, an Autologous iPSC-Derived Neuronal Therapy, in Parkinson's Disease

Clinical Trial Profile Snapshots

Appendix

Abbreviations

Definitions

Research Methodology

Secondary Research

About GlobalData

Contact Us

Source

Table

Parkinson's Disease Therapeutics, Global, Clinical Trials by Region, 2026*

Parkinson's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*

Parkinson's Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*

Parkinson's Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2026*

Parkinson's Disease Therapeutics Clinical Trials, Europe, Top Five Countries, 2026*

Parkinson's Disease Therapeutics Clinical Trials, North America, Top Countries, 2026*

Parkinson's Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2026*

Parkinson's Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2026*

Proportion of Parkinson's Disease to Central Nervous System Clinical Trials, G7 Countries (%), 2026*

Parkinson's Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*

Parkinson's Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*

Proportion of Parkinson's Disease to Central Nervous System Clinical Trials, E7 Countries (%), 2026*

Parkinson's Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*

Parkinson's Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*

Parkinson's Disease Therapeutics, Global, Clinical Trials by Phase, 2026*

Parkinson's Disease Therapeutics, Global, Clinical Trials In Progress by Phase 2026*

Parkinson's Disease Therapeutics, Global, Clinical Trials by Trial Status, 2026*

Parkinson's Disease Therapeutics Clinical Trials, Global, by End Point Status, 2026*

Parkinson's Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2021-2025

Parkinson's Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2026*

Parkinson's Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2026*

Parkinson's Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*

Parkinson's Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*

Figures

Parkinson's Disease Therapeutics, Global, Clinical Trials by Region (%), 2026*

Parkinson's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*

Parkinson's Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*

Parkinson's Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2026*

Parkinson's Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2026*

Parkinson's Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2026*

Parkinson's Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2026*

Parkinson's Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2026*

Proportion of Parkinson's Disease to Central Nervous System Clinical Trials, G7 Countries (%), 2026*

Parkinson's Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*

Parkinson's Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*

Proportion of Parkinson's Disease to Central Nervous System Clinical Trials, E7 Countries (%), 2026*

Parkinson's Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*

Parkinson's Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*

Parkinson's Disease Therapeutics, Global, Clinical Trials by Phase (%), 2026*

Parkinson's Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2026*

Parkinson's Disease Therapeutics, Global, Clinical Trials by Trial Status, 2026*

Parkinson's Disease Therapeutics Clinical Trials, Global, by End Point Status, 2026*

Parkinson's Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2021-2025

Parkinson's Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2026*

Parkinson's Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2026*

Parkinson's Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*

Parkinson's Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*

GlobalData Methodology

Parkinson’s Disease – Global Clinical Trials Review, 2026 standard reports
Currency USD
$3,450

Can be used by individual purchaser only

$10,350

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Parkinson’s Disease – Global Clinical Trials Review, 2026 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Parkinson’s Disease – Global Clinical Trials Review, 2026 in real time.

  • Access a live Parkinson’s Disease – Global Clinical Trials Review, 2026 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.